ACAT1 and familial hypercholesterolemia: The CAPTIVATE trial was another multi-center, randomized, double-blind, placebo-controlled clinical trial which used the ACAT inhibitor pactimibe in 892 patients with heterozygous familial hypercholesterolemia, to assess carotid artery intimal-media thickness at baseline and at 12, 18 and 24 months later [71].